Related Experiment Videos
Cox-2 expression on tissue microarray of breast cancer
1Department of Pathology, Inje University, Sanggye Paik Hospital, 761-1, Sanggye-dong, Nowon-gu, Seoul 139-707, South Korea.
Summary
Cyclooxygenase-2 (Cox-2) over-expression in breast cancer indicates a more aggressive tumor phenotype. This finding suggests Cox-2 may predict resistance to doxorubicin chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Cyclooxygenase-2 (Cox-2) is an enzyme implicated in inflammation and cancer development.
- Its role in breast cancer progression and response to chemotherapy requires further elucidation.
Purpose of the Study:
- To quantify Cox-2 expression in invasive breast cancers.
- To assess Cox-2 as a predictive marker for doxorubicin-based adjuvant chemotherapy efficacy.
Main Methods:
- Immunohistochemistry was performed on tissue microarrays from 178 node-positive breast cancer patients.
- Cox-2 expression levels were correlated with tumor characteristics and patient survival outcomes.
Main Results:
- Cox-2 over-expression was detected in 70 of 178 (39.3%) invasive breast cancers.
- Over-expression was associated with undifferentiated tumors but not tumor size, grade, or estrogen receptor status.
- Patients with Cox-2 expressing tumors had significantly worse disease-free survival (p=0.009) and overall survival (p=0.011).
Conclusions:
- Cox-2 expression may signify an aggressive breast cancer phenotype.
- Elevated Cox-2 levels could indicate resistance to doxorubicin chemotherapy.